Celerion Inc.
Celerion Inc., a leading provider of clinical research services, is headquartered in the United States and operates across major regions including North America and Europe. Founded in 1979, Celerion has established itself in the biopharmaceutical industry, specialising in early clinical research and drug development services. The company offers a range of unique services, including bioanalytical testing, clinical pharmacology, and patient recruitment, which are designed to accelerate the drug development process. Celerion's commitment to innovation and quality has positioned it as a trusted partner for pharmaceutical and biotechnology companies worldwide. With a strong track record of successful studies and a focus on regulatory compliance, Celerion continues to play a pivotal role in advancing healthcare solutions.
DitchCarbon Score
How does Celerion Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celerion Inc.'s score of 23 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celerion Inc.'s reported carbon emissions
Celerion Inc., headquartered in the United States, has made significant commitments towards reducing its carbon emissions and addressing climate change. Although specific emissions data for the most recent year is not available, the company has pledged to ambitious emissions reduction targets in alignment with the Science Based Targets initiative (SBTi). Celerion aims to achieve net-zero emissions across all scopes by 2050, with a commitment to limiting global temperature rise to 1.5°C. The company's long-term climate strategy includes a commitment to the SBTi net-zero standard, which underscores its dedication to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector. Celerion's targets are set to commence in 2023 and extend through to 2050, reflecting a proactive approach to climate action. As of now, Celerion has not reported specific absolute emissions figures, but its commitment to net-zero emissions demonstrates a clear intention to contribute positively to global climate goals. The absence of cascaded emissions data indicates that Celerion is independently managing its climate commitments without reliance on parent or related organizations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celerion Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
